Next-Gen COVID-19 Vaccine Shows Promising Phase 3 Results

Moderna's latest COVID-19 vaccine candidate, mRNA-1283, has demonstrated superior immune responses in its Phase 3 clinical trial, surpassing the performance of the company's existing mRNA-1273.222 vaccine. This achievement is particularly significant for the elderly population, who are most vulnerable to severe COVID-19 outcomes. The trial, known as NextCOVE, involved over 11,000 participants from the United States, the United Kingdom, and Canada, aged 12 and above. The results indicated that mRNA-1283 not only induced a stronger immune reaction against the Omicron BA.4/BA.5 and original SARS-CoV-2 strains but also showed a safety profile akin to Moderna's other approved vaccines.

The success of mRNA-1283 is a testament to Moderna's innovative mRNA platform, which has been instrumental in developing vaccines and therapeutics for a range of diseases, including infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders. The company's commitment to leveraging mRNA technology to revolutionize medicine-making and enhance public health is evident in their rapid and efficient development of life-saving treatments.

Moderna's CEO, Stéphane Bancel, highlighted the importance of mRNA-1283 as a key component of their combination vaccine, mRNA-1083, which aims to protect against both influenza and COVID-19. The positive results from the Phase 3 trial bolster the company's confidence in bringing this vital vaccine to the market.

Furthermore, mRNA-1283's potential for longer shelf life and easier storage could significantly reduce the burden on healthcare providers and increase accessibility in various settings. Detailed insights from the Phase 3 clinical trial are set to be shared at Moderna's Vaccines Day event and future scientific gatherings.

As a pioneer in mRNA medicine, Moderna has been at the forefront of scientific advancements, with a global team united by a shared vision to improve human health through mRNA-based solutions. The company's dedication to responsible innovation and impact is central to its mission, as it continues to explore the vast potential of mRNA technology in treating and preventing diseases.